Former Everest Medicines Executive Sheng Feng Joins GSK China as VP of Market Access and Commercial Operations

(Source: Yidu Pharma)

Source: Yidu Pharma

December 1, 2025: A senior executive change in the pharmaceuticals industry has drawn attention — Sheng Feng, former senior executive of Everest Medicines, officially joins.GSK, a multinational pharmaceutical giant, serves as the Vice President and Head of Market Access & Commercial Operations (MACO) in China.

According to the email, Mr. Sheng Feng will officially join GSK China on December 1, 2025, reporting directly to Vivian Yu, Vice President and General Manager of GSK China, and will become a member of the China Leadership Team (CLT).

Everest Medicines expressed sincere gratitude in an email for Sheng Feng's "outstanding contributions and exceptional leadership" over the past four years. Just a few hours later, GSK's official announcement of the appointment was released, indicating that this personnel change had been planned well in advance.

Sheng Feng is no "new face" in the pharmaceutical industry. Before joining GSK, he served as the Senior Vice President of Government Affairs and Market Access at Everest Medicines, where he achieved significant results in government affairs, strategic planning for new product launches, evidence generation, and driving medical insurance and market access at both central and local levels in China.

Prior to this, he had worked for over 20 years at companies such as Gilead Sciences and Roche. During his tenure at Gilead Sciences, he served as the head of market access and channel management, with broad coverage of multiple business and management functions, including market access, pricing strategy, health economics, channels and supply chain, and key account management.

Mr. Sheng Feng holds a Master's degree in Management from Fudan University and a Bachelor's degree in Medicine from Tongji Medical University.

In 2024-2025, GSK China has completed multiple rounds of high-level adjustments:

July 2024,Yu Huiming Promoted from General Manager of Taiwan Region to Vice President of GSK and General Manager of China, Becoming the Second Local "Leader" in Company History; Former China General Manager Qi Xin (Cecilia Qi) Also Promoted to Vice President of Greater China and Intercontinental Region (GCI) and Head of Vaccines Business.

April 2025,GSK Establishes the Position of "Chief Operating Officer (COO)" in China for the First Time, Appointing Maurizio Borgatta, Former General Manager of Korea, to Join the Leadership Team in Shanghai and Focus on Enhancing Local Operational Efficiency.

July 2025,Ke Yuxiong has been appointed as Vice President of GSK China and Head of Medical Affairs, filling the top-level gap in the R&D and medical evidence chain, marking the completion of a closed loop in the China regional management team at both the "medical" and "pharmaceutical" ends.

December 2025,Sheng Feng joins and serves as the head of Market Access and Commercial Operations (MACO), integrating "market access" and "commercial operations" into a unified function for the first time, aiming to create a closed loop from policy implementation to market execution.

The series of changes show that GSK China is undergoing organizational restructuring through localization, flattening, and synergization, shifting from "product-driven" to "system-driven" in order to lay the groundwork for the scaling up of vaccines, respiratory products, specialty medicines, and potential new oncology products.

In terms of performance, in the third quarter of 2025, GSK achieved a total revenue of £8.547 billion (approximately $11.3 billion), up 8% year-on-year at constant exchange rates. Core operating profit and core earnings per share increased by 11% and 14%, respectively. Specialty medicines sales of £3.4 billion (+16%) were the main driver, with oncology business up 39%, respiratory and immunoinflammation up 15%, and HIV drugs up 12%. Vaccine business revenue was £2.7 billion (+2%), with Shingrix for shingles and Arexvy for RSV increasing by 13% and 36%, respectively. The growth was mainly contributed by Europe and international markets, while sales in China declined due to a temporary reduction in supply.

On the other hand, it is worth noting that,Starting from October 10, 2025, Everest Medicines completed a major shift in "top-level power":Founder Fu Wei, who has chaired the board for eight years, stepped down as chairman of the board, transitioned to become a non-executive director, and was awarded the title of "Honorary Chairman."Fosun PharmaChairman Wu Yifang has been appointed as the Executive Director and Chairman of the Board, while also taking the helm of the Nomination and Remuneration Committees. With this adjustment, Non-Executive Director Feng Honggang has announced his resignation, marking the company's official entry into a new governance cycle jointly led by operating partners from CBC Group and industry veterans.

Everest Medicines' commercialization system has gradually matured, with core products such as Nefukang and Trodelvy successively launched and included in medical insurance. The sales team continues to expand, now covering key medical resources across major provinces and cities in China.

At the strategic level, the company is accelerating its shift from an early focus on "License-in" (external licensing introduction) to a dual-driven model of "independent research and development + BD overseas," with several key pipelines such as BTK inhibitors in the renal disease field, mRNA tumor vaccines, and autologous CAR-T entering the late clinical stage. The next 2-3 years will see a period of intensive harvest.

Against this backdrop, Sheng Feng's departure coincides with the company's governance structure, commercialization layout, and independent R&D system all entering a new phase, which can be regarded as a "graceful exit" in line with the rhythm of corporate development.